A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants

NCT06311656 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: LY4100511 (DC-853)
DRUG: LY4100511 (DC-853)
DRUG: LY4100511 (DC-853)
DRUG: LY4100511 (DC-853)
DRUG: Placebo

Sponsor

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company